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ABSTRACT
Corynebacterium diphtheriae, Pseudomonas aeruginosa, Ricinus communis, Shigella
dysentariae, and Vibrio cholerae produce AB toxins which share the same basic structural
characteristics: a catalytic A subunit attached to a cell-binding B subunit. All AB toxins have
cytosolic targets despite an initial extracellular location. AB toxins use different methods to reach
the cytosol and have different effects on the target cell. Broad-spectrum inhibitors against these
toxins are therefore hard to develop because they use different surface receptors, entry mechanisms,
enzyme activities, and cytosolic targets.
We have found that grape seed extract provides resistance to five different AB toxins:
diphtheria toxin (DT), P. aeruginosa exotoxin A (ETA), ricin, Shiga toxin, and cholera toxin (CT).
To identify individual compounds in grape seed extract that are capable of inhibiting the activities
of these AB toxins, we screened twenty common phenolic compounds of grape seed extract for
anti-toxin properties. Three compounds inhibited DT, four inhibited ETA, one inhibited ricin, and
twelve inhibited CT. Additional studies were performed to determine the mechanism of inhibition
against CT. Two compounds inhibited CT binding to the cell surface and even stripped bound CT
off the plasma membrane of a target cell. Two other compounds inhibited the enzymatic activity of
CT. We have thus identified individual toxin inhibitors from grape seed extract and some of their
mechanisms of inhibition against CT. This work will help to formulate a defined mixture of
phenolic compounds that could potentially be used as a therapeutic against a broad range of AB
toxins.
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CHAPTER 1: INTRODUCTION
Toxins are toxic substances produced by many plants and bacteria. Although there are many
different types of toxins, the current study focuses on a subset of AB toxins, a class of toxins
containing a catalytic A subunit attached to a cell-binding B subunit. AB toxins are the cause of
many diseases. Broad-spectrum inhibitors against AB toxins are hard to develop mainly because
different AB toxins use different receptors, entry mechanisms, and targets. The following subsections will serve as a brief overview of the different AB toxins that were investigated during the
course of this project.

1.1 Corynebacterium diphtheriae and Diphtheria Toxin
C. diphtheriae is a Gram-positive bacterium that secretes the AB-type diphtheria toxin (DT)
[1]. The C-terminal domain of DT contains the B fragment that is subdivided into two domains, a
translocation domain (T) and a receptor binding domain (R) [2]. The catalytic (C) domain of DT is
located in the N-terminus of the toxin. Using its R domain, DTB binds to its heparin-binding
epidermal growth factor (HB-EGF) receptor on the surface of the cell [1, 3, 4]. DT is then
internalized in a clathrin-dependent fashion [5]. The protease furin, which cycles between the cell
surface, endosomes, and TGN, cleaves DT between the C and T domain [5, 6]. After furin’s
cleavage, the C and T domains are still linked via a disulfide bond [5]. In the early endosomes (EE),
the acidic environment causes the T domain to undergo a change in conformation during which the
hydrophobic regions are inserted into the membrane in order to create a channel through which the
C domain translocates to the cytoplasm (Figure 1). In the cytosol, the disulfide bond between the C
and T domains gets reduced [7-9]. Following reduction in the cytosol, the C domain ADPribosylates elongation factor 2 (eEF-2) by transferring an ADP-ribose group from nicotinamide
1

dinucleotide (NAD). Following ADP-ribosylation, eEF-2 becomes inactive, subsequently protein
translation is halted and programmed cell death occurs [10, 11].
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Figure 1: Molecular mechanism of action of DT.
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1.2 Pseudomonas aeruginosa and Exotoxin A
P. aeruginosa is a Gram-negative bacterium that secretes the virulence factor Pseudomonas
exotoxin A [12]. ETA is secreted as a multi-domain single polypeptide. The toxin belongs to the
AB-type toxin family and it is comprised of three main domains: a receptor binding domain (R or
domain I) located in the N-terminus, a translocation domain (T or domain II), and a catalytic
domain (C or domain III) [13-15]. The C terminal domain of ETA contains a REDLK peptide
sequence from which a secreted host carboxypeptidase removes the lysine (K) residue [16].
Following binding via its R domain to the low-density lipoprotein receptor-related protein (LRP)
[17, 18], ETA gets internalized via endocytic vesicles and clathrin-coated pits [19]. ETA is then
cleaved by furin protease in a furin-sensitive loop located in the T domain [6, 20-22]. Following
cleavage by furin, the C and T domains remain linked by a disulfide bond. Reduction of the
disulfide bond by PDI or PDI-like enzyme partially separates the catalytic C domain from the T
domain, allowing the C domain to migrate to the TGN aided by Rab9 [23, 24]. A part of the T
domain still remains bound to the C domain [23, 24]. In the Golgi, the REDL sequence located at
the toxin C-terminus binds to KDEL intracellular sorting receptor, allowing its transport to the ER.
In the ER, part of the T domain still bound to the C domain via a disulfide bond helps translocate
the C domain to the cytoplasm [16, 25, 26]. In the cytosol, the C domain ADP-ribosylates eEF-2,
thereby inactivating it (Figure 2). Inactivation of eEF-2 ultimately leads to inhibition of protein
synthesis and programmed cell death [27].

4

Figure 2: Molecular mechanism of action of ETA.
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1.3 Ricinus communis and Ricin Toxin
Castor bean from the R. communis plant produces ricin toxin as a natural by-product. Ricin
is a type II ribosome inactivating protein (RIP II). Bacteria and, most commonly, plants produce
RIPs. In fact, RIPs have originally been known as an antiviral agent that certain plants like
pokeweed uses [28, 29]. There are several reports of the use of ricin in biological warfare [30].
Ricin is a category B biothreat agent. Currently there are no known countermeasures against ricin
[31, 32]. Ricin is a single chain AB-type toxin composed of an A subunit linked to a B subunit via a
disulfide bond. Ricin binds to galactose or N-acetylgalactolamine residues located on glycoproteins
and glycolipids using its lectin B subunit [33, 34]. Following clathrin-dependent or clathrinindependent endocytosis, ricin gets retrotransported from the EE to the Golgi, and then to the ER
(Figure 3) where its disulfide bond gets reduced [35, 36]. Using the ERAD quality control process,
the A subunit of ricin enters the cytosol via the sec61p translocon [37-39]. In the cytosol, the A
subunit of ricin attacks the ribosome by removing a specific adenine residue (Depurination) from
the 28S rRNA loop known as the “sarcin/ricin loop”. Removal of this adenine residue disrupts the
interaction between the ribosome and eEF-2, causing translation inhibition and ultimately cell death
by apoptosis [40-42]. Also, many studies are being conducted to investigate potential anti-cancer
uses of ricin. Since it causes cell death, scientists are investigating its use in gene therapy and
immunotoxins to selectively target cancer cells [43].

6

Figure 3: Molecular mechanism of action of ricin.
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1.4 Shigella dysentariae and Shiga Toxin
S. dysentariae type 1 is a Gram-negative bacterium that secretes Shiga toxin (ST) as a
virulence factor. S. dysentariae, isolated by Dr. Kiyoshi Shiga in 1896, was the first known species
of Shigella [44-46]. Other types of bacteria such as enterohemorrhagic Escherichia coli (EHEC)
also produce Shiga-like toxins [47]. Shiga toxins are involved in several diseases including
dysentery, Shigellosis, hemolytic uremic syndrome [48], and others [44, 46, 49, 50]. ST belongs to
the family of AB toxins and it has a B binding (STB) subunit and a catalytic A (STA) subunit.
STA1 is connected to STA2 by a disulfide bond just like CT [51, 52]. ST has the same AB5
organization as CT. There are different groups of STs depending on the organism producing the
toxin [50, 53]. ST trafficking involves STB binding to membrane glycolipid Gb3, from which it is
endocytosed through clathrin coats. Furin cleaves STA in the endosomes and/or TGN to generate a
disulfide-linked STA1/STA2 heterodimer. Reduction of the STA1/STA2 disulfide bond in the ER
allows STA1 to dissociate from STA2 before entering the cytosol [47, 54-56]. In the cytosol, STA1
irreversibly inactivates the ribosome by the removal of an adenine residue (Depurination) from the
28S rRNA of the larger 60S ribosomal subunit (Figure 4), thereby inhibiting protein translation and
causing cell death [57, 58].

8

Figure 4: Molecular mechanism of action of ST.
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1.5 Vibrio cholerae and cholera toxin
V. cholerae is a Gram-negative bacterium that causes cholera, a significant water-borne
diarrheal disease. While water is usually considered to be the main route of V. cholera transmission,
it can also be transmitted through contaminated food. Cholera is very rare in industrialized
countries, mainly because of good sanitation. The last major cholera outbreak was the case of Haiti
in 2010 [59]. The main symptom of cholera is water and electrolyte loss caused by the diarrhea. If
not treated, cholera can lead to death. Oral rehydration solutions to replace the loss of fluids and
electrolytes are the main treatment for cholera. Antibiotics are often used as a supplement that helps
reduce the duration and severity of the disease. However, due to the rise of antibiotic-resistant V.
cholerae strains, new low-cost therapies that also reduce the duration and severity of the disease are
needed as an alternative to antibiotics.
Cholera toxin (CT) is the main virulence factor released from V. cholerae [60, 61]. CT is an
AB-type toxin that is released into the lumen of the gut and activates by ADP-ribosylation Gs, the
stimulatory subunit of the heterotrimeric G protein needed to activate adenylate cyclase and the
cAMP signaling pathway [62-64]. The A subunit of CT is a single polypeptide that can be
converted by proteolysis to a disulfide-linked heterodimer consisting of a catalytic CTA1 moiety
and a CTA2 fragment which links CTA1 to the CTB binding domain. The B subunit of CT is a
pentameric ring-like structure that binds to GM1 gangliosides on the eukaryotic plasma membrane
(Figure 5). Once bound to the cell surface, CT is endocytosed and delivered to the endoplasmic
reticulum (ER) through the trans-Golgi network (TGN) by retrograde vesicular transport [60, 62].
Reduction of the CTA1/CTA2 disulfide bond occurs in the (ER) [65, 66], and subsequently allows
protein disulfide isomerase (PDI) to release the CTA1 polypeptide from the rest of the toxin [67,
68]. CTA1 then unfolds, which facilitates its entry to the cytosol by the quality control mechanism
10

of ER-associated degradation (ERAD) [69-72]. Cytosolic CTA1 then initiates the intoxication
process by ADP-ribosylation of Gs. The constitutive activation of adenylate cyclase by Gs leads
to an increased level of cAMP. High levels of cAMP cause the activation of protein kinase A
(PKA), which ultimately leads to the phosphorylation of the cystic fibrosis transmembrane
conductance regulator chloride (CFTR) channel [62, 73-75]. CFTR phosphorylation causes the
channel to open, thereby releasing chloride ions in the intestinal milieu. The release of the chloride
ions, accompanied with water, is what causes the diarrhea response of the cholera disease.

11

Figure 5: Retrograde trafficking of CT.
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1.6 Hypothesis and Aims
All the toxins discussed above share an AB structural organization. All these toxins are
endocytosed from the plasma membrane and reach the cytosol from an intracellular organelle
(Table 1). DT, from C. diphtheriae, moves from an acidified endosome to the cytosol where it
modifies eEF-2 by ADP-ribosylation. This causes an inhibition of protein synthesis in the host cell.
ETA, from P. aeruginosa, moves from the ER to the cytosol to inhibit protein synthesis by ADPribosylation of eEF-2. CT, from V. cholerae, RT from R. communis, and ST from S. dysentariae
enter the cytosol from the ER. RT and ST both inhibit protein synthesis by the removal of a specific
adenine residue in the 28S rRNA of the large 60S ribosomal subunit, thereby rendering the
ribosome unable to interact with eEF-2. CT, on the other hand, targets cytosolic Gs. Despite their
structural similarities, these toxins each have different surface receptors, different intracellular
trafficking mechanisms, and different cytosolic targets. Thus, formulating broad-spectrum
inhibitors for these toxins is difficult.
In many cultures, herbal remedies have been used for centuries to help alleviate diarrheal
diseases like cholera [76, 77]. Dietary consumption of grape products, red wine in particular, has
been shown to be associated with lower incidence of cardiovascular disease and certain types of
cancer. Grape extract possesses many relevant biological activities, such as antioxidant and
antimicrobial properties [78, 79]. Recently, the Teter lab has shown that grape seed extract confers
resistance against CT [80]. Grape seed extract has also been identified to confer resistance against
ST [81]. Because grape seed extract is rich in phenolic compounds [82-84] (Figure 6), we
hypothesized that one or more phenolic compounds from grape extract are responsible for
generating resistance to CT and ST. The present work primarily aimed to identify the specific
phenolic compounds in the extract that are responsible for CT inhibition and to determine the
13

mechanism of inhibition. Another aim of this project was to identify a broad-spectrum inhibition of
the phenolic compounds against other AB-type toxins. The use of antibiotics against bacterial
infection causes a problem because of the selective pressure that they exert on the pathogens that
can give rise to resistant strains. Therefore new approaches are in need to help fight bacterial
pathogens. Natural compound usage against CT, from V. cholerae, is a good approach because,
unlike antibiotics, it will be less likely to induce a selective pressure on the bacterial pathogens that
can lead to resistance because it does not directly affect the growth or viability of the pathogen.
Therefore the present work can be used as a foundation for the synthesis of broad-spectrum
therapeutic agents against cholera and other toxin-mediated diseases.
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Table 1: Toxins comparison chart.

Translocation
Site

Cytosolic
Target

Acidified
Endosomes

eEF-2

ER

eEF-2

ER

28S rRNA
of the 60S
ribosome

Depurination

Gb3 glycolipid

Clathrindependent

ER

28S rRNA
of the 60S
ribosome

Depurination

GM1

Clathrinindependent

ER

Gsα

ADPribosylation

Toxin

Receptor

Endocytosis

DT

HB-EGF

ETA

LRP

Ricin

Glycoproteins/lipids
with terminal
galactose

Clathrindependent and
clathrinindependent

ST
CT

Clathrindependent
Clathrindependent
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Action on
Target
ADPribosylation
ADPribosylation

Figure 6: The chemical structures of 8 phenolic compounds.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Chemicals and Reagents
Amresco (Solon, OH)


4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)



Ammonium persulfate (APS)



Bromophenol blue



Glacial acetic acid



Glycine



Sodium dodecyl sulfate (SDS)



Tris-Cl

Atlanta Biologicals (Lawrenceville, GA)


Fetal bovine serum (FBS)

Bio Rad (Hercules, CA)


40% Acrylamide/Bis solution



AG 50W-X4 ion exchange resin beads

Fisher Scientific (Pittsburgh, PA)


200 proof ethanol (EtOH)



2-mercaptoethanol (β-ME)



4-diethylaminobenzaldehyde



Bovine serum albumin (BSA)



CellTiter 96 AQueous One solution cell proliferation assay (MTS)



Dimethyl sulfoxide (DMSO)
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Forskolin Coleus forskohlii



Gel code blue stain reagent



Glycerol



Methanol (MeOH)



Phosphate monobasic monohydrate (Na2HPO4H2O) tris base



Slide-A-lyzer mini dialysis units (3500 MWCO)



Sodium chloride (NaCl)



Sodium hydroxide (NaOH)



Sodium phosphate dibasic anhydrous (Na2HPO4)



Sodium phosphate dibasic heptahydrate (Na2HPO4·7H2O)



Sodium phosphate monobasic anhydrous (NaH2PO4)

GE Healthcare (Piscataway, NJ)


ELISA cAMP kit

Gibco (Grand Island, NY)


Antibiotic-antimycotic (AA)



Dulbecco’s modified eagle medium (DMEM)

Invitrogen (Carlsbad, CA)


Antibiotic-antimycotic (AA)



Dulbecco’s modified eagle medium (DMEM)



Ham’s F-12



SilverQuest staining kit



Trypsin/EDTA

Mediatech, Inc. (Manassas, VA)
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Phosphate-Buffered Saline, 1X

Pierce Biotechnology, Inc. (Rockford, IL)


BCA protein assay kit

Santa Cruz Biotechnology, Inc.


4-Diethylaminobenzaldehyde



Aminoguanidine bicarbonate

Sigma Aldrich (St. Louis, MO)


-Casein from bovine milk



200 proof ethanol (EtOH)



Aminoguanidine bicarbonate



Ethylenediaminetetraacetic acid (EDTA)



Glycerol



Sodium phosphate dibasic heptahydrate (Na2HPO4·7H2O)



Tetramethylethylenediamine (TEMED)



Thermolysin from Bacillus thermoproteolyticus



Trypan blue solution

2.2 Plant Extracts and Phenolic Compounds (with Stock Concentration and Solvent)
Chromadex, Inc. (Irvine, CA)


Caftaric acid (2.5 mg/ml in H2O)



Cyanidin-3-diglucoside (1 mg/ml in H2O)



Delphinidin-3-O-glucoside (2.5 mg/ml in H2O)



Gallic acid (2.5 mg/ml in H2O)
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Grape (Vitis vinifera) seed XRM (10 mg/ml in H2O)



Kuromanin chloride (2.5 mg/ml in H2O)



Peonidin-3-glucoside chloride (2.5 mg/ml in H2O)



Petunidin-3-glucoside chloride (2.5 mg/ml in H2O)



Procyanidin B1 (2.5 mg/ml in H2O)



(+)-Procyanidin B2 (2.5 mg/ml in H2O)



Protocatechin (2.5 mg/ml in H2O)



Quercitrin (1 mg/ml in EtOH)

Extrasynthese (Genay Cedex, France)


Kaempferol-3-Glucoside (2.5 mg/ml in MeOH)



Malvin chloride (2.5 mg/ml in MeOH + 0.1% HCl)



Oenin chloride (2.5 mg/ml in MeOH + 0.1% HCl)

Polyphenolics, Inc. (Madera, CA)


Gold grape seed extract (10 mg/ml in H2O)

Sigma Aldrich (St. Louis, MO)


(-)-Catechin (2.5 mg/ml in H2O)



(-)-Catechin gallate (2.5 mg/ml in H2O)



(-)-Epicatechin (2.5 mg/ml in H2O)



(-)-Epicatechin gallate from green tea (2.5 mg/ml in H2O)



(-)-Epigallocatechin gallate (2.5 mg/ml in H2O)



Resveratrol (2.5 mg/ml in EtOH)
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2.3 Buffers
4X SDS-PAGE Sample Loading Buffer


0.04% bromophenol blue



0.1 M 2-mercaptoethanol (ß-ME)



0.24 M tris-HCl, pH 6.8



40% glycerol



8% SDS

10X Phosphate Buffered Saline (PBS)


0.69 M NaCl



0.17 M NaH2PO4



0.58 M Na2HPO4

10X SDS-PAGE Running Buffer


0.025 M tris base



0.1% SDS



0.192 M glycine

2.4 Toxins
List Biological Laboratories (Campbell, CA)


Cholera toxin, A subunit



Cholera toxin, holotoxin



Diphtheria toxin



Exotoxin A from Pseudomonas aeruginosa



Shiga toxin 2
21

Sigma Aldrich (St. Louis, MO)


Cholera holotoxin



Cholera toxin A subunit



Fluorescein isothiocyanate-conjugated CTB pentamer (FITC-CTB)

Vector Laboratories (Burlingame, CA)


Ricinus communis agglutinin II

2.5 Equipments
Bio Rad (Hercules, CA)


Bio Rad PowerPac Basic



Bio Rad PowerPac HC



Gel Doc 2000

BioTek Instruments (Winooski, VT)


Synergy 2 plate reader

2.6 Cell Lines


Chinese hamster ovary (CHO) cells



Vero cells



Vero-d2EGFP cells

2.7 Data Processing Softwares


Adobe photoshop



KaleidaGraph



Microsoft excel
22

2.8 Other Materials
VWR International (Aurora, CO)


10 cm tissue culture dish



24-well tissue culture plate



6-well tissue culture plate



Cellstar, 96-well cell culture plate



Costar assay plate, 96-well black-walled with clear flat bottom



Fisher scientific hemocytometer

2.9 Techniques
Cell Culture
All cells were split when they reached about 80% confluency. This confluency was usually
reached every 3 to 4 days for the cells used. Cells in a 10 cm dish were washed once with phosphate
buffered saline (PBS). Following the PBS wash, 1 ml of trypsin-EDTA was added for about 5
minutes in order to lift the cells from the dish. For CHO cells, 9 mls of Ham’s F-12 medium
containing 10% FBS and 1% AA was added to resuspend the cells. For Vero and Vero-d2EGFP
cells, 9 mls of Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS and 1% AA was
added to resuspend the cells. For each new 10 cm dish, 9 mls of the appropriate medium and 1 ml
of cell resuspension were added. Evenly distributed cells in the 10 cm dish were then placed in a
37ºC incubator under 5% CO2. For the 96-well plate, a 1:10 dilution of the 10 ml cell suspension
was used to seed the plate (100 μl per well). For the 24-well plates, a 1:5 dilution of the 10 ml cell
suspension was used to seed the plate (500 μl per well for the 24 well-plates). 80% confluency was
reached within 18 to 24 hours prior to intoxication.
23

cAMP Toxicity Assay
Flat bottom 24-well plates were used to seed CHO cells in triplicate. The cells reached 80%
confluency after an overnight incubation. After one wash with PBS, Ham’s F-12 serum-free
medium with various dilutions of CT in the presence or absence of treatments was added to the
plate. After incubation the cells were washed again with PBS. 15 minute incubation with 0.25 ml of
ice cold HCl: EtOH (1:100) at 4ºC was used to lyse the cells. The cell extracts were transferred to
new 24-well plates and allowed to air dry overnight. Following reconstitution in assay buffer, the
levels of cAMP were determined by using the ELISA cAMP competition assay kit as described by
the manufacturer. Unintoxicated cells were used to establish the background level of cAMP. The
background level was subtracted from each cAMP value, and these values were expressed as
percentages of the maximum response from untreated CHO cells, which was arbitrarily set as the
100% value.
Measurement of Cell Viability with the MTS Assay
To monitor cell viability in the presence of phenolic compounds, CHO cells were seeded in
a 96-well plate and allowed to reach ~80% confluency overnight at 37ºC under 5% CO2. The next
day, cells were treated in the presence or absence of 10 μg/ml dilution of the specified phenolic
compounds in serum-free F-12 medium for an additional overnight incubation at 37ºC. The day
after, 20 μl of a commercially available MTS reagent was added to each well of the plate for a 3
hour incubation at 37ºC. NADPH and NADH from live, metabolically active cells reduce the MTS
reagent into a colored formazan product that can be detected at an absorbance of 490 nm using a
Synergy 2 plate reader. The formazan absorbance at 490 nm is directly proportional to the extent of
cell viability.
Toxin Binding Assay
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Vero cells grown to 80% confluency in 96-well clear-bottom black-walled plates were
treated with 100 μl of 1 μg/ml dilution of FITC-CTB in serum-free DMEM media at 4°C in the
presence or absence of drug treatments for 1 hour. Following the incubation, the cells were washed
with PBS. A Synergy 2 plate reader was used to measure the fluorescence intensity using 485/20
nm excitation and 528/20 nm emission wavelength filters. A set of untreated Vero cells was used as
the background fluorescence level and was subtracted from each value. To investigate whether or
not the grape seed extract, PB2 or EGCG could strip bound FITC-CTB off the cell surface, the
FITC-CTB was allowed to bind to the cell surface for 30 minutes at 4°C before the addition of the
individual treatment conditions. For the dialysis experiment, a 3.5 kD mini dialysis cup was used.
Specific conditions were added to the dialysis cup and allowed to dialyze overnight in PBS (pH
7.4). The next day the contents of the dialysis cup were added to Vero cells for 1 hour at 4°C
followed by PBS washes before the fluorescence intensity measurement.
In Vitro CTA1 Activity Assay
To monitor the ADP-ribosyltransferase activity of CTA1, aminoguanidine bicarbonate and
4-diethylaminobenzaldehyde were used to synthesize diethylamino(benzylidine-amino)guanidine
(DEA-BAG), a substrate for ADP-ribosylation [85]. DEA-BAG was synthesized by making a 0.11
M solution of aminoguanidine bicarbonate, pH 6.5. After filtration to remove insoluble solids, the
solution was heated to 60°C. 4-Diethylaminobenzaldehyde in 200 proof EtOH was added to the
filtrate in a 1:1 molar ratio with the aminoguanidine bicarbonate (Figure 7). The solution was
allowed to stir at room temperature overnight, and the precipitated DEA-BAG was harvested by
filtration, lyophilized, and placed at -80°C for long-term storage.
Specified conditions of CTA samples were diluted in 0.2 M KH2PO4, pH 7.5 with 0.02 M
DTT, 0.1 mg/ml BSA, 0.01 M NAD, and 0.02 M DEA-BAG. After a 2 hour incubation at room
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temperature, AG 50W-X4 ion exchange resin beads was added to the reaction. Unmodified DEABAG binds to the resin beads, whereas ADP-ribosylated DEA-BAG does not. A tabletop centrifuge
was used to spin the samples at maximum speed for 15 minutes. The supernatant from the samples
were used to measure the extent of ADP-ribosylation of DEA-BAG (Figure 8). The intrinsic
fluorescence of DEA-BAG was measured using a Synergy 2 plate reader at 360 nm excitation and
460 nm emission wavelengths. A set of DEA-BAG with no CTA treatment was used as the
background fluorescence level and was subtracted from each value.
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Figure 7: The synthesis of DEA-BAG.
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Figure 8: In vitro DEA-BAG assay.
A) When DEA-BAG is ADP-ribosylated by CTA1 it is unable to bind the resin beads and remains in the supernatant
following application of a centrifugal force.
B) Unmodified fluorescent DEA-BAG binds the resin beads and migrates to the bottom of the tube when a centrifugal
force is applied.
The fluorescent intensity of the supernatant is thus directly related to the extent of toxin activity.
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Protease Sensitivity Assay
The thermolysin assay is used to monitor the folding state of CTA1 (Figure 9). The basis
behind this assay is that an unfolded protein is less resistant to protease activities than a folded
protein. Upon addition of the thermolysin protease to the samples, unfolded CTA1 will be degraded
and no band will be present when resolved on a gel, whereas folded CTA1 is more resistant to
proteolysis and shows up as a band on a gel.
A 20 mM NaPO4 buffer (pH 7.4) with 10 mM β-ME was used to reduce the 1 μg CTA
samples. The samples (20 μl) were then incubated under specified temperatures for an hour. After
the 1 hour incubation the samples were allowed to equilibrate at 4°C for 10 minutes. Following the
4°C equilibration, the protease reaction was conducted by adding 2 μl from a 0.4 mg/ml
thermolysin protease solution in 0.05 M CaCl2 and 0.1 M HEPES (pH 8.0) to the samples for an
additional 1 hour 4°C incubation. To halt the protease reaction, 3 μl of a 0.1 M EDTA was added to
the samples for 5 minutes 4°C incubation. After adding 5 μl from a 4X SDS-PAGE loading buffer
to the samples, the samples were boiled for 5 minutes. Following boiling, 25 μl from the 30 μl total
final volume was resolved using a 12% SDS-PAGE gel, and Coomassie staining was used for
visualization.
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Figure 9: Thermolysin assay for CTA1 unfolding.
Panel A: Phenolic compounds that do not inhibit CTA1 unfolding at 37°C will not protect CTA1 from
thermolysin.
Panel B: Phenolic compounds that inhibit CTA1 unfolding at 37°C will protect CTA1 from thermolysin.
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Vero-d2EGFP Assay
The Vero-d2EGFP assay is a fluorescence-based toxicity assay that was used to monitor
protein synthesis in the presence of DT, ETA, ricin, and ST. As described by Quiñones et al. [81],
the Vero-d2EGFP cells were seeded in a 96-well black-walled plate with clear flat bottom and
incubated overnight in a 37°C humidified incubator under 5% CO2. The next day, the cells reached
~ 80% confluency. After a PBS wash, the cells were treated with specific toxins diluted in serumfree Ham’s F-12 medium. After an additional overnight incubation at 37°C, the cells were washed
three times with PBS. Following the PBS washes, a Synergy 2 plate reader with the 485/20 nm
excitation filter and the 528/20 nm emission filter was used to measure EGFP fluorescence level.
The fluorescence level of EGFP was expected to be inversely proportional to the activity of the
toxins (Figure 10). A set of unintoxicated parental Vero cells was used as the background EGFP
signal and was subtracted from each value. The values are expressed as a percentage of the
maximum fluorescent signal from Vero-d2EGFP cells incubated in the absence of toxin, which was
set as the 100% value.
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Figure 10: Vero-d2EGFP to monitor protein synthesis activity.
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CHAPTER 3: RESULTS
Quiñones et al. have reported that grape seed extract can reduce the activity of ST in
cultured cells [81]. Therefore the Vero-d2EGFP assay was used to further investigate the anti-toxin
properties of grape seed extract against other AB toxins, namely DT, ETA and ricin. The cell line
used here expresses a variant of GFP with a 2 hour half-life. The toxins under study block protein
synthesis, so there is an inverse correlation between toxin activities and the GFP signal. An increase
in the toxins’ activity will result in lower GFP signal, and vice versa. Unintoxicated Vero-d2EGFP
cells are arbitrarily set as the 100% maximal EGFP signal value, and all the individual values are
expressed as a ratio of that maximal EGFP signal. A 100 μg/ml grape seed extract concentration
was used to investigate the anti-toxin property of the grape seed extract against each of these toxins.
This is the same concentration used in the Quiñones et al. paper.

3.1 Grape Seed Extract Inhibits the Activity of DT, ETA and Ricin
Using the Vero-d2EGFP assay, we intoxicated the cells with DT to generate a dose-response
curve. The EC50 was determined to be ~0.01 ng/ml (Figure 11). When the cells were intoxicated
along with a 100 μg/ml grape seed extract concentration, the activity of DT was significantly
reduced. An ED50 could not be calculated for DT intoxication in the presence of grape seed extract.
When compared to nearly a complete loss of fluorescence signal for DT alone at 0.1 ng/ml, the
fluorescence signal was still ~90% of the untreated signal. This suggests a high resistance to DT.
A dose-response curve was generated for Vero-d2EGFP cells treated with ETA. The EC50 of
ETA was ~35 ng/ml (Figure 12). ETA-intoxicated cells treated with a 100 μg/ml concentration of
grape seed extract showed a higher level of protein synthesis compared to untreated cell samples,
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with about 75% of the untreated fluorescent signal remaining in Vero-d2EGFP cells exposed to the
highest ETA concentration of 100 ng/ml.
A dose-response curve was generated for Vero-d2EGFP cells treated with ricin. The EC50 of
ricin was found to be ~0.05 ng/ml (Figure 13). When the cells intoxicated with ricin were treated
with grape seed extract, a higher level of protein synthesis was detected. About 60% of the
untreated fluorescence signal was detected in Vero-d2EGFP cells exposed to both 1 ng/ml ricin and
grape extract, compared to a nearly complete loss of protein fluorescence signal in cells exposed to
1 ng/ml of ricin alone.
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Figure 11: The effect of DT on Vero-d2EGFP signal.
EGFP signal was measured after an overnight incubation with the indicated concentrations of DT. Error bar
represents the means of 3-5 independent experiments with 6 or 12 replicate samples for each condition. The
circle denotes Vero-d2EGFP samples intoxicated with DT only, and the square denotes the co-incubation of
DT with grape seed extract.
The EGFP signal from untreated Vero-d2EGFP cells was arbitrarily set as the 100% maximal EGFP signal.
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Figure 12: The effect of ETA on Vero-d2EGFP signal.
EGFP signal was measured after an overnight incubation with the indicated concentrations of ETA. Error bar
represents the means of 3-5 independent experiments with 6 replicate samples for each condition. The circle
denotes untreated Vero-d2EGFP samples intoxicated with ETA only, and the square denotes the addition of
grape seed extract along with ETA.
The EGFP signal from untreated Vero-d2EGFP cells was arbitrarily set as the 100% maximal EGFP signal.
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Figure 13: The effect of ricin on Vero-d2EGFP signal.
EGFP signal was measured after an overnight incubation with the indicated concentrations of ricin. Error bar
represents the standard errors of the means of 3-5 independent experiments with 6 replicate samples for each
condition. The circle denotes untreated Vero-d2EGFP samples intoxicated with ricin only, and the square
denotes the addition of grape seed extract.
The EGFP signal from untreated Vero-d2EGFP cells was arbitrarily set as the 100% maximal EGFP signal.
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3.2 Phenolic Compounds’ Screens against DT, ETA, Ricin, and ST
We demonstrated that the grape seed extract confers resistance against 4 different toxins,
namely DT, ETA, ricin, and ST. Since the extract contains substantial quantities of phenolic
compounds [82-84], our hypothesis was that these phenolic compounds are responsible for the toxin
resistance. Upon advice from Drs. Friedman and Quiñones from the USDA whom are experts in
phenolic compound studies, we chose to screen a set of 20 individual phenolic compounds along
with the toxins in order to determine the active components of the grape seed extract that are
responsible for toxin inhibition. A set of unintoxicated cells and a set of cells treated with 10%
glycerol were used as controls. The 10% glycerol solution was used as a positive control. Glycerol
is a known protein stabilizer that prevents unfolding of the toxins’ catalytic domain that is required
for translocation to the cytosol [48, 81].
To monitor the anti-DT property of the individual phenolic compounds, a 0.1 ng/ml
concentration of DT was used to intoxicate the cells. When cells were treated with 0.1 ng/ml DT
alone, the EGFP signal was lowered to 17 ± 2%. Three of the individual compounds screened,
epigallocathechin gallate, caftaric acid, and procyanidin B1, lowered the activity of DT and
consequently maintained elevated EGFP signals of 59 ± 3%, 46 ± 9%, and 46 ± 9% of the
unintoxicated control value, respectively (Table 2). To monitor the anti-ETA property of the
individual phenolic compounds, a 100 ng/ml concentration of ETA was used to intoxicate the Verod2EGFP cells. Four of the 20 compounds screened, epicatechin gallate, epigallocathechin gallate,
procyanidin B2, and resveratrol showed elevated EGFP signals of 73 ± 12%, 89 ± 10%, 84 ± 13%,
and 46 ± 5% of the unintoxicated control value, respectively. This was compared to 22 ± 4% of the
control EGFP signal obtained from Vero-d2EGFP cells intoxicated with ETA in the absence of
phenolic compounds (Table 2). We then screened the 20 individual phenolic compounds to
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determine which ones confer resistance against ricin. To monitor the anti-ricin property of the
individual phenolic compounds, a 1 ng/ml concentration of ricin was used to intoxicate the Verod2EGFP cells. Only one of the compounds screened, epigallocathechin gallate, showed protection
against the activity of ricin with an EGFP signal of 51 ± 10% compared to 19 ± 2% for untreated,
ricin-intoxicated Vero-d2EGFP cells (Table 2). Our data show that epigallocathechin gallate
confers resistance against multiple toxins, whereas epicatechin gallate, caftaric acid, procyanidin
B1, procyanidin B2, and resveratrol affect only one toxin. This observation suggests that the
effectiveness of the extract stems from the fact that it contains many different compounds, each
affecting one or more toxins.
No individual compound conferred resistance against ST. However, a cocktail of all 20
compounds conferred resistance against ST with an EGFP signal of 52 ± 4% compared to 32 ± 2%
for untreated, ST-intoxicated Vero-d2EGFP cells (Table 2). This suggests that two or more
compounds in the extract act synergistically to inhibit ST.
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Table 2: Phenolic compounds screened against ST, ricin, ETA, and DT.
(David Curtis, Chris Britt, Chris Berndt, and Srikar Reddy also contributed to these data).
- Each value represents the mean of at least three independent experiments with 6 or 12 replicate samples for each condition.
- ± denotes standard error of the mean (SEM).
- Red denotes statistical significance (p<0.01, student’s t test).

% Control EGFP Signal
(Maximal EGFP Signal- no toxin addition)

Compound (10 μg/ml)
No Treatment
10% Glycerol
Catechin
Catechin gallate
Epicatechin
Epicatechin gallate
Epigallocatechin gallate
Caftaric acid
Gallic acid
Procyanidin B1
Procyanidin B2
Quercitrin
Cyanidin
Delphinidin
Kaempferol
Protocatechin
Resveratrol
Kuromanin
Malvin
Oenin
Peonidin
Petunidin
20 compound cocktail

Molarity
(μM)

ST

Ricin

ETA

DT

--34
23
34
23
22
32
58
17
17
22
31
30
35
65
44
21
15
19
20
20
--

32 ± 2
83 ± 9
33 ± 7
39 ± 7
30 ± 4
38 ± 2
40 ± 3
28 ± 1
27 ± 4
25 ± 4
27 ± 2
22 ± 3
30 ± 6
34 ± 6
32 ± 5
29 ± 7
33 ± 8
24 ± 3
29 ± 6
27 ± 5
30 ± 8
31 ± 10
52 ± 4

19 ± 2
84 ± 4
22 ± 5
22 ± 5
20 ± 4
17 ± 5
51 ± 10
25 ± 6
28 ± 6
14 ± 2
16 ± 3
15 ± 1
14 ± 2
17 ± 2
15 ± 4
12 ± 3
20 ± 4
19 ± 5
17 ± 3
15 ± 2
18 ± 4
17 ± 4
--

22 ± 4
92 ± 4
22 ± 3
15 ± 2
16 ± 2
73 ± 12
89 ± 10
15 ± 3
17 ± 8
20 ± 4
84 ± 13
15 ± 3
14 ± 3
15 ± 5
20 ± 6
13 ± 4
46 ± 5
9±3
28 ± 7
24 ± 5
27 ± 7
13 ± 1
--

17 ± 2
57 ± 7
20 ± 3
19 ± 2
18 ± 4
28 ± 4
59 ± 3
46 ± 9
33 ± 7
46 ± 9
15 ± 4
9±4
13 ± 3
31 ± 7
19 ± 3
8±4
10 ± 2
20 ± 1
14 ± 2
17 ± 1
14 ± 1
15 ± 1
--
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3.3 Inhibition of CT Activity by Phenolic Compounds
Reddy et al. have found that grape seed extract confers resistance to CT intoxication [80].
We therefore used a cocktail of 20 compounds to confirm that this inhibition is in fact mediated by
phenolic compounds. The data show that our cocktail did in fact significantly lower the cAMP
response induced by CT to ~20% of the response generated from cells exposed to 100 ng/ml CT in
the absence of the cocktail (Figure 14). To identify the individual compounds responsible for CT
inhibition, 10 μg/ml of each of the individual compounds was screened for a block of the CTinduced cAMP accumulation. A greater than 50% cAMP reduction in control cAMP levels was set
as an arbitrary cut off for toxin inhibition. Twelve of the compounds screened were found to meet
this criterion (Table 3). To investigate whether the compounds affect the activity of adenylate
cyclase (AC), we screened mixtures of each compound with forskolin, a known AC agonist [86].
One of the compounds, PB2, was found to partially inhibit the activity of AC. This indicated that
PB2, but none of the other 11 compounds, could potentially affect CT activity through an indirect
effect linked to the inhibition of AC activity. We then investigated other mechanisms by which the
12 compounds could inhibit CT. Different stages in the CT intoxication process, namely binding to
the cell surface, unfolding of CTA1, and CTA1 ADP-ribosylation activity, were investigated (Table
3). By monitoring the fluorescence from a FITC-CTB pentamer bound to the surface of Vero cells,
two of the compounds, PB2 and EGCG, were found to partially inhibit binding of CT to the cell
surface (58 ± 8% and 57 ± 9% of control signal, respectively). Two other compounds, caftaric acid
and kaempferol, partially inhibited the ADP-ribosylation activity of CTA1 (45 ± 7% and 53 ± 4%
of control signal, respectively) as measured by an in vitro assay for toxin activity. While the grape
seed extract itself prevents the unfolding of CTA1, no individual compounds inhibited the
unfolding of CTA1 with the thermolysin protease sensitivity assay. A cocktail of the twelve
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phenolic inhibitors of CT also failed to prevent the unfolding activity of CTA1 by the same
thermolysin assay. As shown by an MTS viability assay, none of the twelve hit compounds affected
cell viability (Table 3). DMSO is known to be toxic to cells; therefore 20% DMSO was used as a
negative control during each MTS viability assay. Only about 2% of the control signal remained
when cells were treated with 20% DMSO (Data not shown).
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Figure 14: A cocktail of 20 phenolic compounds confers resistance against CT.
- CHO cells were used over a 2 hour incubation period at 37°C under specified conditions. Error bar represents
the standard error of the mean of 3 independent experiments with 3 replicate samples for each condition.
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Table 3: Phenolic compounds screened against different stages of CT intoxication.
(Camila Garcia also contributed to these data)
- Phenolic compounds screened against in vivo CT activity (cAMP), toxin binding to the cell surface (FITC-CTB), and in vitro CTA1 activity
(DEA-BAG).
- Potential toxicity of each compound was screened with an MTS viability assay.
- The % control signal in each assay was arbitrarily set at the 100% value. For cAMP, this value represents the amount of cAMP produced in
CHO cells when treated with 100 ng/ml of CT over a 2 hour incubation period at 37°C. For viability, this value represents the absorbance at 490
nm when MTS reagent is added to untreated CHO cells. For FITC-CTB, this value represents the fluorescence signal of FITC-CTB when Vero
cells are treated with 1 µg/ml of FITC-CTB for 30 minutes at 4°C. For DEA-BAG, this value represents the fluorescence signal of DEA-BAG at
25°C with 1µg/ml of CTA1 for 2 hours.
- ± denotes the standard error of the mean (SEM) of at least 2 independent experiments or the standard deviation of the number of replicate
samples of a single experiment. For cAMP it represents the SEM of at least 2 independent experiments with 3 replicate samples or the SD of 3
replicate samples of 1 experiment. For MTS viability, FITC-CTB, and DEA-BAG, it represents the SEM of at least 3 independent experiments
with 6 or 12 replicate samples.
- Bold value represents compounds with anti-CT property.

% Control Signal
Compound (10 μg/ml)

Molarity
(μM)

cAMP

Viability

FITC-CTB

DEA-BAG

Catechin
Oenin chloride
Malvin chloride
Epicatechin gallate
Peonidin
Protocatechin
Epicatechin
Catechin gallate
Petunidin
Quercitrin
Caftaric acid
Kaempferol
Procyanidin B2
Procyanidin B1
Gallic Acid
Kuromanin
Resveratrol
Delphinidin
Cyanidin
Epigallocatechin gallate
Seed extract

34
19
15
23
20
65
34
23
20
22
32
35
17
17
58
21
44
30
31
22
--

98 ± 4
86 ± 11
74 ± 18
74 ± 11
73 ± 3
72 ± 4
67 ± 14
63 ± 8
44 ± 2
41 ± 8
39 ± 9
35 ± 9
31 ± 7
30 ± 3
24 ± 1
23 ± 15
22 ± 7
15 ± 5
10 ± 10
7±3
23 ± 1

--------100 ± 4
97 ± 3
103 ± 2
117 ± 2
102 ± 7
94 ± 2
103 ± 7
97 ± 4
99 ± 5
105 ± 5
102 ± 4
88 ± 4
--

--------94 ± 4
80 ± 5
83 ± 7
78 ± 6
58 ± 8
79 ± 8
77 ± 5
78 ± 6
89 ± 10
69 ± 6
79 ± 5
57 ± 9
20 ± 3

--------65 ± 5
78 ± 8
45 ± 7
53 ± 4
99 ± 1
69 ± 3
107 ± 5
102 ± 2-108 ± 3
76 ± 10
113 ± 13
101 ± 6
22 ± 7
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PB2 and EGCG Inhibit FITC-CTB Binding
As previously established by Reddy et al. [80], grape seed extract prevents binding of CT to
the cell surface. Therefore, the grape seed extract was used as a positive control for additional CT
binding assays. We found that a cocktail of PB2 and EGCG, or a cocktail of the twelve hit
compounds (the ones that lowered the control cAMP level below 50%) partially inhibited the
binding of FITC-CTB on the surface of Vero cells in a dose-dependent manner (Figure 15A). At
100 μg/ml, 10 μg/ml, and 1 μg/ml, the twelve compound cocktail inhibited binding of CT to the cell
surface by 37 ± 2%, 64 ± 8%, and 86 ± 2% of the control signal, respectively. At 17, 1.7, and 0.17
µg/ml, the PB2/EGCG cocktail inhibited binding of CT to the cell surface by 23 ± 9%, 57 ± 6%,
and 87 ± 2% of the control signal, respectively. At a concentration of 17 μg/ml, the PB2/EGCG
cocktail was found to be as effective as 100 μg/ml of the seed extract at inhibiting FITC-CTB
binding. The molar amounts of PB2 and EGCG used in both the two compound and the twelve
compound cocktails are equivalent, and yet the EGCG/PB2 cocktail exhibits the same potency as
the twelve hit compound cocktail. Therefore, it appears nothing else in the twelve compounds
cocktail other than PB2 and EGCG is contributing to the inhibition of FITC-CTB binding.
Reddy et al. also established that grape seed extract can strip bound CT off the cell surface
[80]. To investigate whether PB2 and EGCG alone or in a cocktail could strip bound FITC-CTB
from the cell surface, they were added 30 minutes after FITC-CTB had been bound to the cell
surface. The binding of FITC-CTB to the cell surface is conducted at 4°C to avoid the
internalization of the bound FITC-CTB. A cocktail made with the twelve hit compounds was also
investigated to see if it could strip bound FITC-CTB off the cell surface. These cocktails and
individual compounds did in fact strip bound CT off the cell surface (Figure 15B).
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To investigate the affinity of the grape seed extract and the two compounds for FITC-CTB,
we did a dialysis experiment. A 3.5 kD molecular weight cut off dialysis tube was used to dialyze
FITC-CTB overnight in the presence or absence of treatments. With a strong affinity for the FITCCTB, the grape seed extract and compounds would have remained bound to the toxin and still
confer resistance after dialysis. Unlike the seed extract that exhibited a high affinity interaction with
FITC-CTB that allowed it to be retained after overnight dialysis, both PB2 and EGCG did not show
this high affinity (Figure 15C). After the overnight dialysis, PB2 and EGCG showed a weaker
inhibition. This is due perhaps to the loss of some of the compounds after the dialysis. The extract,
on the other hand, gets slightly more effective after dialysis. This is perhaps due to the removal of
one or more compounds that inhibit the anti-toxin compounds. Since both PB2 and EGCG lost most
of their effects after the dialysis, there must be other anti-toxin compound(s) in the extract that were
not investigated during the course of this project.
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Figure 15: Toxin binding experiments.
Toxin binding to Vero cells in the presence of grape extract, a cocktail of 12 phenolic compounds, a cocktail of 2
phenolic compounds, and two individual compounds. A) The FITC-CTB subunit was co-incubated with the
phenolic compounds and seed extract, then applied to Vero cells for 1 hour at 4°C, a temperature that allows
toxin binding to the cell surface but prevents toxin endocytosis. B) Addition of seed extract (100 μg/ml), 12
compound cocktail (100 μg/ml),or 2 compound cocktail (17 μg/ml) for 1 hour at 4°C after a 30 minutes 4°C
incubation of FITC-CTB and Vero cells. C) Dialysis experiment showing that one or more compounds in the
seed extract (100 μg/ml) exhibits a high affinity interaction with the CTB subunit that allows the seed
compound(s) to be retained after overnight dialysis. Neither PB2 (10 μg/ml) nor EGCG (10 μg/ml) showed this
high affinity with CTB.
Error bar represents the standard error of the mean (SEM) of at least 3 independent experiments with 6 or 12
replicate samples for each condition.
The FITC-CTB signal from cells incubated with FITC-CTB in the absence of phenolic compounds was set as the
100% value.
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No Individual Compounds or Cocktails Inhibit the Thermal Unfolding of CTA1
The free CTA1 subunit needs to unfold in order to leave the ER and reach its target in the
cytosol. To monitor this unfolding event, the thermolysin protease sensitivity assay was used. As
previously established [80], grape seed extract prevented the thermal unfolding of CTA1 (Figure
16A). However, none of the individual compounds or cocktails that we screened were found to
inhibit the unfolding of CTA1 (Figure 16A and data not shown). Thus, another compound (or
compounds) in the extract must be responsible for the inhibition of CTA1 unfolding. Further
experiments confirmed the extract-induced inhibition of CTA1 unfolding was not due to an
inhibition of the thermolysin protease itself. For this control experiment, the milk protein α-casein
was used, mainly because it has relatively little secondary structure and will always be degraded in
the presence of an active protease. Our results confirm that the grape seed extract does not interfere
with the thermolysin protease activity (Figure 16B), as the presence of grape extract did not inhibit
the proteolysis of α-casein.

48

B

Figure 16: Thermal unfolding of CTA1 at 37°C.
A) The grape seed extract inhibits the thermal unfolding of CTA1, but no individual compounds or cocktails
screened inhibit unfolding of CTA1.
1: CTA1 only
2: Thermolysin only
3: Disulfide-linked CTA1/CTA2 heterodimer, which also prevents CTA1 unfolding
4: + 100 µg/ml grape seed extract
5: + 1000 µg/ml grape seed extract
6: + 11 compound cocktail (Quercitrin, Caftaric acid, Kaempferol, PB2, PB1, Gallic Acid, Kuromanin,
Resveratrol, Delphinidin, Cyanidin, EGCG) at 100 µg/ml
7: + PB2 (10 µg/ml)
8: + EGCG (10 µg/ml)
Although results for only two individual compounds are shown, none of the individual twelve hit compounds
prevented the thermal unfolding and proteolysis of CTA1.
B) The grape seed-induced inhibition of CTA1 unfolding is not due to an inhibition of the thermolysin protease.
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CHAPTER 4: DISCUSSION
The present work has evaluated the use of grape seed extract as an anti-toxin agent against
cholera and other toxin-mediated diseases. Other plant extracts, including unripe fruit of Aegle
marmelos, have also been shown to possess antibacterial properties [12, 80]. The grape seed extract
used in our study is sold as a nutritional supplement and is generally regarded safe by the United
States Food and Drug Administration [87, 88]. In the present work we identified individual
phenolic compounds of the grape seed extract that inhibit CT activity, and we also determined some
of their mechanisms of action. We also provide evidence that individual phenolic compounds from
the grape seed extract contribute to broad-spectrum toxin inhibition against ST, ricin, ETA, and DT.
This work provides a foundation for the synthesis of broad-spectrum therapeutic drugs against
cholera and other toxin-mediated diseases.
None of the individual compounds screened against ST was found to be inhibitory to its
activity. However, a cocktail made of all 20 compounds was found to partially inhibit the cytotoxic
effect of ST. This finding suggests some of the compounds in the grape seed extract might act
synergistically to inhibit ST. A single compound, EGCG was found to provide a broad-spectrum
resistance against ricin, ETA, DT, and CT. The cellular basis of EGCG-generated resistance to
these toxins remains to be established. Furthermore, although EGCG did not confer resistance
against Shiga toxin 2 that we used in this study, it has recently been reported that EGCG inhibits the
cytotoxicity of Shiga toxin 1, a less potent isoform of Shiga toxin [89].
We identified twelve compounds that block CT. None of these twelve compounds has any
significant effect on cell viability. The mechanism by which the twelve compounds block CT was
investigated. Two of the compounds inhibited binding of CT, EGCG and PB2. Two other
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compounds, caftaric acid and kaempferol, inhibited the enzymatic activity of CT. Our data further
showed that grape seed extract has a high binding interaction with FITC-CTB. However, the high
binding interaction of the grape seed extract with FITC-CTB could not be replicated with the two
individual compounds that inhibited binding of FITC-CTB, PB2 and EGCG. This suggests that
there might be more than one compound acting synergistically to provide this effect, or there are
other compounds in the extract providing this high affinity interaction that were not screened in this
study. As seen in Figure 15C, the seed extract provided a better protection after dialysis as
compared to the non-dialyzed seed extract. This finding suggests that the overnight dialysis might
have helped remove some of the compounds in the grape seed extract that have a negative effect on
the anti-toxin compounds present in the extract. This finding also suggests that a defined cocktail
might be better than the extract for therapeutic use, because of the absence of the inhibitors of the
anti-toxin compounds.
The seed extract, PB2 and EGCG have the ability to remove bound FITC-CTB off the
plasma membrane of the cell. The mechanism of action of this phenomenon still remains to be
elucidated, but it again shows the high affinity that the seed extract exhibits for CT. It also suggests
that EGCG, PB2, and the seed extract can provide protection even after being exposed to CT. There
are potential concerns that certain phenolic compounds can induce protein aggregation [90], but our
data suggest that the hit compounds at the 10 µg/ml concentration are specific as anti-toxins. If the
anti-toxin compounds were inducing non-specific toxin aggregations, they would aggregate all the
toxins that were investigated and inhibit their activities, not just a subset of the toxins. Also,
compounds at 10 µg/ml are not toxic to cells as confirmed by MTS cell viability assays.
Unlike the seed extract, no individual compound screened was found to inhibit the unfolding
of CTA1, a necessary step that allows the toxin to leave the ER and reach the cytosol. However, our
51

data do confirm that a subset of the compounds have the ability to block multiple events in the
cholera intoxication process. Two compounds interfered with the binding of CT to the cell surface,
and two different compounds partially inhibited the ADP-ribosylation activity of CTA1. The
finding of compounds that inhibit the enzymatic activity of CTA1 further suggests that these
compounds might still be effective after being exposed to CT. Although we identified twelve
compounds with anti-CT property, we were only able to determine the mechanism of inhibition of
four of them. Because neither of the remaining eight compounds could inhibit FITC-CTB binding,
prevented unfolding, or prevented the ADP-ribosylation of DEA-BAG, the mechanism of inhibition
of these eight compounds must be independent of CT binding, CTA1 unfolding, and CTA1
enzymatic activity.
Recently, there have been growing interests in studying the health benefits of plant extracts.
Recent studies have investigated the beneficial properties of various plant extracts. Hop extract, for
example, has been investigated against Alzheimer in mice [91], and it is also commercially
available as a dietary supplement [92]. Another study has also investigated the anti-CT property of
resveratrol, a phenolic compound present in grape seed extract [93]. The mechanism behind the
health benefits of most extracts is unknown. Our work on natural products is unique in that it does
not only identify toxin inhibitors; it also investigates potential mechanism of action. We have
previously shown that grape seed extract inhibits multiple events in the cholera intoxication
process. We have also shown that grape seed extract reduces the CT-induced intestinal fluid
accumulation using an in vivo animal model [80]. The present work identified grape seed extract as
a broad-spectrum anti-toxin. The broad-spectrum anti-toxin provided by grape seed extract stems
from the fact that a majority of the extract is composed of phenolic compounds. Different phenolic
compound with anti-toxin property affects different toxin at different step in the toxin intoxication
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process. Furthermore, we identified phenolic compounds in grape seed extract with anti-toxin
properties for five different toxins. Lastly, we identified how a subset of phenolic compounds
inhibits CT.
In conclusion, this work has evaluated the use of grape seed extract as an anti-toxin agent
against cholera and other diseases caused by AB toxins. We identified individual phenolic
compounds of grape seed extract that inhibit CT activity, and we determined some of their
mechanisms of action. We have also provided evidence that individual phenolic compounds from
grape seed extract contribute to broad-spectrum toxin inhibition against ST, ricin, ETA, and DT.
This present work provides a foundation for the synthesis of broad-spectrum therapeutic drugs
against cholera and other toxin-mediated diseases.
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